Protease inhibitors as cancer chemopreventive agents:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York u.a.
Plenum Press
1993
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XVIII, 315 S. Ill., graph. Darst. |
| ISBN: | 0306443902 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV008331037 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 931115s1993 ad|| |||| 00||| engod | ||
| 020 | |a 0306443902 |9 0-306-44390-2 | ||
| 035 | |a (OCoLC)28182453 | ||
| 035 | |a (DE-599)BVBBV008331037 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-20 | ||
| 050 | 0 | |a RC268.15 | |
| 082 | 0 | |a 616.99/405 |2 20 | |
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Protease inhibitors as cancer chemopreventive agents |c ed. by Walter Troll ... |
| 264 | 1 | |a New York u.a. |b Plenum Press |c 1993 | |
| 300 | |a XVIII, 315 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben | ||
| 650 | 7 | |a Farmacotherapie |2 gtt | |
| 650 | 7 | |a Inhibitie |2 gtt | |
| 650 | 7 | |a Kanker |2 gtt | |
| 650 | 7 | |a Proteïnasen |2 gtt | |
| 650 | 4 | |a Cancer |x Chemoprevention | |
| 650 | 4 | |a Neoplasms |x prevention & control | |
| 650 | 4 | |a Protease Inhibitors |x metabolism | |
| 650 | 4 | |a Protease Inhibitors |x therapeutic use | |
| 650 | 4 | |a Protease inhibitors |x Therapeutic use | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Proteaseinhibitor |0 (DE-588)4130450-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 0 | 2 | |a Proteaseinhibitor |0 (DE-588)4130450-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Troll, Walter |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005503501&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-005503501 | ||
Datensatz im Suchindex
| _version_ | 1804122725077221376 |
|---|---|
| adam_text | C PROTEASE INHIBITORS AS CANCER CHEMOPREVENTIVE AGENTS EDITED BY WALTER
TROLL NEW YORK UNIVERSITY MEDICAL CENTER NEW YORK, NEW YORK AND ANN R.
KENNEDY UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE PHILADELPHIA,
PENNSYLVANIA PLENUM PRESS * NEW YORK AND LONDON CONTENTS CHAPTER 1 THE
EPIDEMIOLOGIC APPROACH TO THE STUDY OF PROTEASE INHIBITORS 1 ELIZABETH
FONTHAM AND PELAYO CORREA 1. INTRODUCTION 1 2. DESCRIPTIVE EPIDEMIOLOGY
1 3. ANALYTICAL EPIDEMIOLOGY 2 4. TOOLS NEEDED FOR EPIDEMIOLOGIC STUDIES
4 5. INTERVENTION STUDIES 5 6. CANCER PREVENTION 6 7. EPILOGUE 6 8.
REFERENCES 7 CHAPTER 2 ANTICARCINOGENIC ACTIVITY OF PROTEASE INHIBITORS:
OVERVIEW 9 ANN R. KENNEDY 1. REVIEW OF DATA SHOWING ANTICARCINOGENIC
ACTIVITY OF PROTEASE INHIBITORS 9 2. POTENTIAL ADVERSE EFFECTS OF
ANTICARCINOGENIC PROTEASE INHIBITORS 15 2.1. EFFECTS OF PROTEASE
INHIBITORS ON GROWTH 15 2.2. EFFECTS OF PROTEASE INHIBITORS ON THE
PANCREAS 16 2.3. POTENTIAL EFFECTS OF PROTEASE INHIBITORS ON THE IMMUNE
SYSTEM 22 3. THE SOYBEAN-DERIVED BBI AS AN ANTICARCINOGENIC AGENT 23
3.1. REVIEW OF DATA ON THE ANTICARCINOGENIC ACTIVITY OF BBI 23 XII
CONTENTS 3.2. LIMITATIONS OF BBI AS A HUMAN CANCER CHEMOPREVENTIVE AGENT
44 4. MECHANISM OF ACTION OF THE ANTICARCINOGENIC PROTEASE INHIBITORS 50
5. SUMMARY 54 6. REFERENCES 55 CHAPTER 3 IN VITRO STUDIES OF
ANTICARCINOGENIC PROTEASE INHIBITORS 65 ANN R. KENNEDY 1. INTRODUCTION
65 2. MECHANISM OF ACTION OF THE ANTICARCINOGENIC PROTEASE INHIBITORS IN
THE SUPPRESSION OF TRANSFORMATION IN VITRO 80 3. REFERENCES 86 CHAPTER 4
DISCOVERY AND BACKGROUND OF THE BOWMAN-BIRK PROTEASE INHIBITORS 93
DONALD E. BOWMAN 1. ORIGIN OF INTEREST IN LEGUMES 93 2. UNEXPECTED
PROTEASE INHIBITION BY AMYLASE INHIBITION PREPARATIONS 93 3. REFERENCES
95 CHAPTER 5 PROTEASE INHIBITORS OF PLANT ORIGIN AND ROLE OF PROTEASE
INHIBITORS IN HUMAN NUTRITION: OVERVIEW 97 YEHUDITH BIRK 1. INTRODUCTION
97 2. PROTEASE INHIBITORS FROM LEGUME SEEDS 98 2.1. STI 98 2.2. BBI 98
3. PROTEASE INHIBITORS FROM OTHER PLANT SOURCES 101 3.1. POTATO PROTEASE
INHIBITORS 101 3.2. SQUASH PROTEASE INHIBITORS 101 3.3. PROTEASE
INHIBITORS IN CEREALS 101 4. ROLE IN NUTRITION 102 4.1. EFFECT ON GROWTH
102 4.2. EFFECTS ON THE PANCREAS 102 CONTENTS XIII 5. THERAPEUTIC
POTENTIAL OF PROTEASE INHIBITORS 103 6. REFERENCES 104 CHAPTER 6-
ANTIGENICITY OF SOYBEAN PROTEASE INHIBITORS 107 DAVID L. BRANDON, ANNE
H. BATES, AND MENDEL FRIEDMAN 1. INTRODUCTION 107 2. KUNITZ TRYPSIN
INHIBITOR 108 2.1. IMMUNOCHEMISTRY OF KTI 108 2.2. SPECIFICITIES OF
MONOCLONAL ANTIBODIES TO KTI 109 3. IMMUNOCHEMISTRY OF THE BOWMAN-BIRK
INHIBITOR 113 3.1. SOURCES AND TREATMENT OF PROTEASE INHIBITORS 114 3.2.
POLYCLONAL ANTIBODIES 114 3.3. MONOCLONAL ANTIBODIES TO BBI 114 3.4.
RELATIONSHIP OF INHIBITORY ACTIVITIES AND ANTIGENICITY 116 4.
IMMUNOASSAYS OF KTI AND BBI 117 4.1. ANTIBODY TITRATIONS, INHIBITION
ELISA, AND COMPETITION ELISA 117 4.2. SANDWICH ELISA 117 4.3.
AVAILABILITY OF CELL LINES 119 5. EXAMPLES OF USE OF MONOCLONAL
ANTIBODIES TO ANALYZE SOY FOODS AND GERM PLASM 119 5.1. AUTOCLAVED SOY
MEAL 119 5.2. INFANT FORMULA 120 5.3. IMMUNOAFFINITY METHODS 121 5.4.
SCREENING THE GENUS GLYCINE 122 6. OTHER EFFECTS OF FOOD PROCESSING ON
ANTIGENICITY OF KTI 122 6.1. CHEMICAL CHANGES DURING FOOD PROCESSING 122
6.2. EFFECTS OF ALKALI 124 6.3. EFFECTS OF CARBOHYDRATES 124 7.
CONCLUSIONS 125 8. REFERENCES 126 CHAPTER 7 LOW-MOLECULAR-WEIGHT
PROTEASE INHIBITORS OF MICROBIAL ORIGIN 131 KAZUO UMEZAWA, TAKAAKI
AOYAGI, WATARU TANAKA, AND TOMIO TAKEUCHI 1. INTRODUCTION 131 2.
ENDOPEPTIDASE INHIBITORS 132 3. EXOPEPTIDASE INHIBITORS 135 4.
REFERENCES 138 XIV CONTENTS CHAPTER 8 PROTEASE INHIBITOR SYNTHESIS BY
MCF-7 BREAST CANCER CELLS 141 THOMAS H. FINLAY, SUSAN S. KADNER, AND
SNAIT TAMIR 1. INTRODUCTION AND SCOPE OF THE CHAPTER 141 2. A,-AT AND
A,-ACHY 144 2.1. FUNCTION AND PROPERTIES 144 2.2. SITE OF SYNTHESIS 145
2.3. REGULATION OF SYNTHESIS 146 3. A,-AT AND A,-ACHY IN MCF-7 CELLS 147
3.1. MCF-7 BREAST CANCER CELL LINE 147 3.2. SYNTHESIS OF A,-AT AND
A,-ACHY BY MCF-7 CELLS 148 3.3. KINETICS OF A R AT AND A,-ACHY SYNTHESIS
AND SECRETION 149 3.4. STIMULATION OF A,-AT AND A,-ACHY SYNTHESIS BY
STEROID HORMONES, INFLAMMATORY MEDIATORS, AND GROWTH FACTORS .... 149
3.5. PRODUCTION OF A R AT AND A,-ACHY BY VARIOUS MCF-7 SUBLINES 153 4.
PERSPECTIVES AND CONCLUSIONS 153 5. REFERENCES 154 CHAPTER 9 ANALYSIS OF
STRUCTURE-ACTIVITY RELATIONSHIPS OF THE BOWMAN*BIRK INHIBITOR OF SERINE
PROTEINASES: TOWARD A RATIONAL DESIGN OF NEW CANCER CHEMOPREVENTIVE
AGENTS 161 PETER FLECKER 1. INTRODUCTION 161 2. BIOLOGICAL ASPECTS 162
3. PROSPECTS OF PROTEIN ENGINEERING FOR THE DESIGN OF ANTICARCINOGENIC
AGENTS 164 4. A NEW APPROACH TO BBI-TYPE PROTEINASE INHIBITORS BY
SYNTHETIC GENE TECHNOLOGY 165 5. TRYPSIN-SEPHAROSE AS A MATRIX WITH
COMPLEMENTARY STRUCTURE IS REQUIRED FOR REFOLDING OF PROTEINASE
INHIBITOR VARIANTS 168 6. BBI HAS STRUCTURAL SIMILARITY TO THE
COOH-TERMINAL PART OF THE B CHAIN OF LAMININ 172 7. CONCLUSIONS 173 8.
REFERENCES 174 CONTENTS XV CHAPTER 10 PREVENTION OF CANCER BY VITAMIN B
3 (NICOTINAMIDE AND NICOTINIC ACID): A PROTEASE INHIBITOR AVAILABLE IN
PURE FORM 177 WALTER TROLL 1. INTRODUCTION 177 2. DIETARY PIS SUPPRESS
CANCER 178 3. INTERFERENCE WITH OXYRADICAL FORMATION 178 4. SUPPRESSION
OF TRANSFORMATION-CAUSED ONCOGENE TRANSFECTION .... 180 5. SUPPRESSION
OF CARCINOGENESIS 181 5.1. SUPPRESSION OF TWO-STAGE CARCINOGENESIS BY
APPLYING PIS TO MOUSE SKIN 181 5.2. SUPPRESSION OF TWO-STAGE
CARCINOGENESIS AND BREAST CANCER IN RODENTS BY FEEDING SOYBEAN DIETS 181
5.3. SUPPRESSION OF TUMOR PROMOTION IN MICE BY FEEDING NA- SUPPLEMENTED
DIETS 185 6. MECHANISM OF CANCER PREVENTION BY FEEDING PIS 185 7.
CONCLUDING REMARKS 186 8. REFERENCES 187 CHAPTER 11 APPROACHES TO
STUDYING THE TARGET ENZYMES OF ANTICARCINOGENIC PROTEASE INHIBITORS 191
PAUL C. BILLINGS 1. INTRODUCTION 191 2. RESULTS AND DISCUSSION 192 2.1.
DEFINED SUBSTRATES AS TOOLS TO IDENTIFY PROTEOLYTIC ACTIVITIES WHICH ARE
INHIBITED BY THE ANTICARCINOGENIC PROTEASE INHIBITORS 192 2.2. THE USE
OF AFFINITY CHROMATOGRAPHY TO IDENTIFY PROTEINS WHICH SPECIFICALLY
INTERACT WITH ANTICARCINOGENIC PROTEASE INHIBITORS 194 3. REFERENCES 197
CHAPTER 12 ANTICARCINOGENIC ACTIVITIES OF NATURALLY OCCURRING CYSTEINE
PROTEINASE INHIBITORS 199 RITA COLELLA, ANN F. CHAMBERS, AND DAVID T.
DENHARDT 1. INTRODUCTION 199 2. CYSTEINE PROTEINASES 200 XVI CONTENTS 3.
THE CYSTATIN SUPERFAMILY 202 4. MODE OF INHIBITION 205 5. CYSTATINS AND
METASTASIS 206 6. REFERENCES 211 CHAPTER 13 CELL MEMBRANE ENZYMES
CONTAINING CHYMOTRYPSIN-LIKE ACTIVITY 217 JONATHAN YAVELOW, LORRAINE T.
SCHEPIS, JOSEPH NICKELS, JR., AND GEORGE RITCHIE 1. INTRODUCTION 217 2.
EFFECT OF CHYMOTRYPSIN INHIBITORS ON IN VITRO CELL TRANSFORMATION 218 3.
PROPERTIES OF CELL MEMBRANE ENZYMES CONTAINING CHYMOTRYPSIN- LIKE
ACTIVITY 220 4. POTENTIAL CELLULAR SUBSTRATES FOR MEMBRANE
CHYMOTRYPSIN-LIKE ENZYMES 221 5. FLUORESCENCE ANISOTROPY AS A TOOL FOR
STUDYING THE ANTICARCINOGENIC ACTION OF CHYMOSTATIN 222 6. CONCLUSIONS
223 7. REFERENCES 223 CHAPTER 14 THE ROLE OF REACTIVE OXYGEN SPECIES IN
BIOLOGICAL DAMAGE AND THE EFFECT OF SOME CHEMOPREVENTIVE AGENTS 227
KRYSTYNA FRENKEL 1. FORMATION OF REACTIVE OXYGEN SPECIES 227 2.
FORMATION OF H 2 O 2 AND OXIDIZED DNA BASES 229 2.1. BY TUMOR
PROMOTER-STIMULATED PMNS 229 2.2. BY HEPATIC MICROSOMES 232 3.
INHIBITION OF H 2 O 2 FORMATION BY STIMULATED PMNS 235 3.1. INHIBITION
BY PROTEASE INHIBITORS 237 3.2. INHIBITION BY SARCOPHYTOL A 242 4.
REFERENCES 243 CHAPTER 15 PROTEASE INHIBITOR SUPPRESSION OF RAS
ONCOGENE-INDUCED TRANSFORMATION 251 SEYMOUR J. GARTE, LYDIA COX, DIANE
C. CURRIE, JOAN MOTZ, AND WALTER TROLL 1. INTRODUCTION 251 2. METHODS
253 2.1. CELL CULTURE AND DNA ISOLATION 253 CONTENTS XVII 2.2.
DNA-MEDIATED TRANSFECTION 253 2.3. CHARACTERIZATION OF TRANSFORMED
PHENOTYPE 253 2.4. SOUTHERN BLOT HYBRIDIZATION 254 2.5. NORTHERN BLOT
HYBRIDIZATION 254 3. RESULTS 255 3.1. DOSE RESPONSE OF PROTEASE
INHIBITORS ON RAS TRANSFORMATION 255 3.2. EFFECTS ON APH GENE
TRANSFECTION 256 3.3. TIME COURSE STUDIES 256 3.4. INFLUENCE OF CELL
PROLIFERATION 257 3.5. SUBCULTURE AND SERUM CONDITIONS 257 3.6.
REVERSIBILITY 258 3.7. RAS GENE EXPRESSION 258 3.8. RETINOIC ACID
EFFECTS 258 4. DISCUSSION 259 5. REFERENCES 261 CHAPTER 16 SUPPRESSION
OF C-MYC BY ANTICARCINOGENIC PROTEASE INHIBITORS 265 JANICE D. CHANG AND
ANN R. KENNEDY 1. INTRODUCTION 265 2. THE ONCOGENE C-MYC AND MALIGNANT
TRANSFORMATION 265 2.1. ACTIVATION OF C-MYC 266 2.2. FUNCTION OF THE
NORMAL C-MYC GENE 267 2.3. MECHANISM OF C-MYC REGULATION 270 3. C-MYC
EXPRESSION IS REDUCED IN PROTEASE INHIBITOR-TREATED PROLIFERATING MOUSE
FIBROBLASTS 270 4. CELLS PROGRESS THROUGH THE CELL CYCLE IN THE ABSENCE
OF AN INCREASE IN C-MYC RNA LEVELS 272 5. ANTIPAIN INCREASES THE
HALF-LIFE OF THE C-MYC MESSAGE 274 6. POSSIBLE MECHANISMS BY WHICH
PROTEASE INHIBITORS REGULATE C-MYC EXPRESSION , 275 7. CONCLUDING
REMARKS 276 8. REFERENCES 277 CHAPTER 17 A ROLE FOR ESTERASES IN STEROID
HORMONE TURNOVER 281 MORTIMER LEVITZ, SILA BANERJEE, JOSEPH KATZ, UMA
RAJU, AND THOMAS H. FINLAY 1. INTRODUCTION AND SCOPE OF THE CHAPTER 281
2. ENDOGENOUS STEROID ESTERS 282 XVIII CONTENTS 2.1. STEROID ESTERS IN
BODY FLUIDS 282 2.2. STEROID ESTERS IN TISSUES 282 2.3. STEROID FATTY
ACID ESTER PRODUCTION IN VITRO 283 3. STEROID ESTER METABOLISM:
PHYSIOLOGICAL IMPLICATIONS 283 3.1. IN MAN 283 3.2. IN MCF-7 CELLS 284
4. ESTERIFICATION AND DEESTERIFICATION ENZYMES 284 5.
TRANSESTERIFICATION 285 6. BREAST CYST FLUID ESTERASE 287 7.
PERSPECTIVES AND CONCLUSIONS 289 8. REFERENCES 292 CHAPTER 18 PROTEASE
INHIBITORS AND PANCREATIC CARCINOGENESIS 295 B. D. ROEBUCK AND DANIEL S.
LONGNECKER 1. PANCREATIC CANCER 295 1.1. HUMAN DISEASE 295 1.2. ANIMAL
MODELS OF PANCREATIC CANCER 296 1.3. CHOLECYSTOKININ HYPOTHESIS 297 2.
RESPONSE OF THE PANCREAS TO TRYPSIN INHIBITORS 298 2.1. SOYBEAN PRODUCTS
298 2.2. CAMOSTATE (FOY-305) 298 3. CARCINOGENESIS AND CHOLECYSTOKININ
299 3.1. RAT PANCREAS 299 3.2. OTHER SPECIES INCLUDING HUMANS 300 4.
CONCLUSION 300 5. REFERENCES 301 INDEX 305
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV008331037 |
| callnumber-first | R - Medicine |
| callnumber-label | RC268 |
| callnumber-raw | RC268.15 |
| callnumber-search | RC268.15 |
| callnumber-sort | RC 3268.15 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 3200 |
| ctrlnum | (OCoLC)28182453 (DE-599)BVBBV008331037 |
| dewey-full | 616.99/405 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/405 |
| dewey-search | 616.99/405 |
| dewey-sort | 3616.99 3405 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01886nam a2200505 c 4500</leader><controlfield tag="001">BV008331037</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">931115s1993 ad|| |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0306443902</subfield><subfield code="9">0-306-44390-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)28182453</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV008331037</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC268.15</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/405</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Protease inhibitors as cancer chemopreventive agents</subfield><subfield code="c">ed. by Walter Troll ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York u.a.</subfield><subfield code="b">Plenum Press</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVIII, 315 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacotherapie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inhibitie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kanker</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proteïnasen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Chemoprevention</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">prevention & control</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protease Inhibitors</subfield><subfield code="x">metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protease Inhibitors</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protease inhibitors</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Proteaseinhibitor</subfield><subfield code="0">(DE-588)4130450-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Proteaseinhibitor</subfield><subfield code="0">(DE-588)4130450-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Troll, Walter</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005503501&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-005503501</subfield></datafield></record></collection> |
| id | DE-604.BV008331037 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:18:26Z |
| institution | BVB |
| isbn | 0306443902 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-005503501 |
| oclc_num | 28182453 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-20 |
| owner_facet | DE-355 DE-BY-UBR DE-20 |
| physical | XVIII, 315 S. Ill., graph. Darst. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Plenum Press |
| record_format | marc |
| spelling | Protease inhibitors as cancer chemopreventive agents ed. by Walter Troll ... New York u.a. Plenum Press 1993 XVIII, 315 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Literaturangaben Farmacotherapie gtt Inhibitie gtt Kanker gtt Proteïnasen gtt Cancer Chemoprevention Neoplasms prevention & control Protease Inhibitors metabolism Protease Inhibitors therapeutic use Protease inhibitors Therapeutic use Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Proteaseinhibitor (DE-588)4130450-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Chemotherapie (DE-588)4127083-6 s Proteaseinhibitor (DE-588)4130450-0 s DE-604 Troll, Walter Sonstige oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005503501&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Protease inhibitors as cancer chemopreventive agents Farmacotherapie gtt Inhibitie gtt Kanker gtt Proteïnasen gtt Cancer Chemoprevention Neoplasms prevention & control Protease Inhibitors metabolism Protease Inhibitors therapeutic use Protease inhibitors Therapeutic use Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd Proteaseinhibitor (DE-588)4130450-0 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4127083-6 (DE-588)4130450-0 |
| title | Protease inhibitors as cancer chemopreventive agents |
| title_auth | Protease inhibitors as cancer chemopreventive agents |
| title_exact_search | Protease inhibitors as cancer chemopreventive agents |
| title_full | Protease inhibitors as cancer chemopreventive agents ed. by Walter Troll ... |
| title_fullStr | Protease inhibitors as cancer chemopreventive agents ed. by Walter Troll ... |
| title_full_unstemmed | Protease inhibitors as cancer chemopreventive agents ed. by Walter Troll ... |
| title_short | Protease inhibitors as cancer chemopreventive agents |
| title_sort | protease inhibitors as cancer chemopreventive agents |
| topic | Farmacotherapie gtt Inhibitie gtt Kanker gtt Proteïnasen gtt Cancer Chemoprevention Neoplasms prevention & control Protease Inhibitors metabolism Protease Inhibitors therapeutic use Protease inhibitors Therapeutic use Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd Proteaseinhibitor (DE-588)4130450-0 gnd |
| topic_facet | Farmacotherapie Inhibitie Kanker Proteïnasen Cancer Chemoprevention Neoplasms prevention & control Protease Inhibitors metabolism Protease Inhibitors therapeutic use Protease inhibitors Therapeutic use Krebs Medizin Chemotherapie Proteaseinhibitor |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005503501&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT trollwalter proteaseinhibitorsascancerchemopreventiveagents |